Nā huahana

Ua hōʻike ʻia ka n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) a me docosahexaenoic acid (DHA) e hoʻonui i ka hopena o nā lāʻau chemotherapeutic i nā haʻawina hauʻoli i nā maʻi maʻi maʻi a me ka hoʻoulu ʻana i ka apoptotic tumor cell death in vitro.A hiki i kēia manawa, ʻaʻole i noiʻi ʻia ka EPA a me DHA i ka myeloma lehulehu (MM).Ua ʻike ʻia nā cell myeloma kanaka (L363, OPM-1, OPM-2 a me U266) a me nā cell mononuclear blood peripheral maʻamau i ka EPA a me DHA, a ua ana ʻia nā hopena i ka hana mitochondrial a me apoptosis, caspase-3 activation, gene expression a me ka lāʻau make.ʻO ka hōʻike ʻana i ka EPA a me DHA i hoʻokomo i ka apoptosis a me ka hoʻonui ʻana i ka naʻau i ka bortezomib i nā cell MM.ʻO ka mea nui, ʻaʻole lākou i hoʻopilikia i ka viability o nā cell mononuclear peripheral maʻamau.Ua hōʻike ʻo Messenger RNA expression arrays ua hoʻololi ʻo EPA a me DHA i nā genes i komo i nā ala hōʻailona he nui me ka nuclear factor (NF) κB, Notch, Hedgehog, oxidative stress a me Wnt.Ua kāohi ʻo EPA a me DHA i ka hana NFκB a hoʻokomo i ka apo ptosis ma o ka mitochondrial perturbation a me ka caspase-3 activation.Hōʻike kā mākou haʻawina e hoʻoulu ʻo EPA a me DHA i nā hopena cytotoxic koho i MM a hoʻonui i ka naʻau i ka bortezomib a kāhea aku no ka ʻimi hou ʻana i kahi noi kūpono o kēia n-3 polyunsaturated fatty acids i ka therapy o MM.